Mr. Peter Cicala is the Chief Patent Counsel and Vice President of Intellectual Property at Celgene Corporation. His legal practice focuses on all aspects of pharmaceutical and biotechnology intellectual property law. He has extensive experience in patent litigation, prosecution, product lifecycle management, R&D collaborations and joint ventures in the pharma/biotech industry. Mr. Cicala has particular expertise with Hatch-Waxman Paragraph IV litigation as well as substantial experience with patent and regulatory litigation in Europe. Mr. Cicala has regularly participated in due diligence investigations, patent, trademark and copyright licensing, as well as M&A transactions and patent litigation settlements. Additionally, Mr. Cicala has over 10 years of experience as a medicinal chemist and has worked in drug development programs for several major pharmaceutical companies and universities.
A person listed as a contributor has spoken or otherwise participated in Federalist Society events, publications, or multimedia presentations. A person's appearance on this list does not imply any other endorsement or relationship between the person and the Federalist Society. In most cases, the biographical information on a person's "contributor" page is provided directly by the person, and the Federalist Society does not edit or otherwise endorse that information. The Federalist Society takes no position on particular legal or public policy issues. All expressions of opinion by a contributor are those of the contributor.
Administrative "Death Squads" for Patents? Assessing the New Administrative Procedures for Challenging Patents
Intellectual Property Practice Group and George Mason University School of Law's Center for the Protection of Intellectual PropertyTeleforum
Administrative "Death Squads" for Patents? Assessing the New Administrative Procedures for Challenging Patents - Podcast
Intellectual Property Practice Group Podcast
Property rights in patented inventions are being struck down at an unprecedented rate in a...